公开(公告)号：US20220257783A1

公开(公告)日：2022-08-18

申请号：US17688707

申请日：2022-03-07

Applicant: BioNTech SE

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sebastian Kreiter

IPC: A61K47/64 ,  C07K14/47 ,  C07K14/74 ,  A61K48/00

Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

公开(公告)号：US20230193296A1

公开(公告)日：2023-06-22

申请号：US18049593

申请日：2022-10-25

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Silke Holtkamp ,  Ozlem Tureci ,  Sebastian Kreiter

IPC: C12N15/68 ,  C12N15/67 ,  C12N15/85

CPC classification number: C12N15/68 ,  C12N15/67 ,  C12N15/85

Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

公开(公告)号：US11298426B2

公开(公告)日：2022-04-12

申请号：US15895402

申请日：2018-02-13

Applicant: BioNTech SE

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sebastian Kreiter

IPC: A61K47/64 ,  A61K48/00 ,  C07K14/74 ,  C12N15/62 ,  C12N5/10 ,  C07K14/47 ,  C12N5/0783

Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.